Diagnostics stocks surge on Covid scare; Dr. Lal PathLabs, Vijaya Diagnostic rise up to 8%
Among diagnostics companies, Vijaya Diagnostic Centre topped the gainers’ chart, followed by Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies.
Revenue of diagnostics firms to fall 5-7% on fewer Covid-19 tests: Report
Decline in revenue along with higher operating expenses, largely marketing and advertisement related, will lead to moderation in operating margins to pre-pandemic levels.
Indian diagnostics market set to double to $20 billion by FY26
Of the $10 billion worth market, standalone centres account for 48% market share, followed by hospital labs with 37% share and national chains with 5% share.
Predictions 2022: Diagnostics to be centrestage of healthcare
Healthcare facilities were forced outside hospital boundaries in the pandemic, leading to a rise in home diagnostics, but there is a need of a more analytical approach in managing, gathering data
Building the Metropolis of the future
Ameera Shah's Metropolis Healthcare is all set to acquire Hitech Diagnostics Centre. Here's Fortune India's earlier story on how Shah is transforming her fast-growing pathlab company.
Mylab: The startup in the limelight
The Pune-based company is pioneering the production of test kits to screen for Covid-19. With fresh funding, it hopes to rapidly ramp up capacity.
How technology can help India become healthier
Technologies like artificial intelligence and machine learning can help in diagnosis, treatment protocol development, drug development, personalised medicine, and patient monitoring and care.
Metropolis Healthcare lists at a premium
The stock opened at ₹960 per share on the BSE, a premium of 9% over its issue price of ₹880.